JP2016519933A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016519933A5 JP2016519933A5 JP2016513129A JP2016513129A JP2016519933A5 JP 2016519933 A5 JP2016519933 A5 JP 2016519933A5 JP 2016513129 A JP2016513129 A JP 2016513129A JP 2016513129 A JP2016513129 A JP 2016513129A JP 2016519933 A5 JP2016519933 A5 JP 2016519933A5
- Authority
- JP
- Japan
- Prior art keywords
- genetically engineered
- blood cell
- enucleated blood
- engineered enucleated
- erythrocyte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000601 blood cell Anatomy 0.000 claims 19
- 210000003743 erythrocyte Anatomy 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 108091005703 transmembrane proteins Proteins 0.000 claims 7
- 102000035160 transmembrane proteins Human genes 0.000 claims 7
- 108010052285 Membrane Proteins Proteins 0.000 claims 6
- 102000018697 Membrane Proteins Human genes 0.000 claims 6
- 210000003617 erythrocyte membrane Anatomy 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102100035716 Glycophorin-A Human genes 0.000 claims 2
- 108091005250 Glycophorins Proteins 0.000 claims 2
- 108091005956 Type II transmembrane proteins Proteins 0.000 claims 2
- 230000015271 coagulation Effects 0.000 claims 2
- 238000005345 coagulation Methods 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000035602 clotting Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019182854A JP6960177B2 (ja) | 2013-05-10 | 2019-10-03 | ソルタギング可能なタンパク質を有する赤血球のｉｎ ｖｉｔｒｏ生成 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361822071P | 2013-05-10 | 2013-05-10 | |
| US61/822,071 | 2013-05-10 | ||
| PCT/US2014/037554 WO2014183071A2 (en) | 2013-05-10 | 2014-05-09 | In vitro production of red blood cells with sortaggable proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019182854A Division JP6960177B2 (ja) | 2013-05-10 | 2019-10-03 | ソルタギング可能なタンパク質を有する赤血球のｉｎ ｖｉｔｒｏ生成 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016519933A JP2016519933A (ja) | 2016-07-11 |
| JP2016519933A5 true JP2016519933A5 (https=) | 2017-06-22 |
| JP6599848B2 JP6599848B2 (ja) | 2019-10-30 |
Family
ID=51867887
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016513129A Expired - Fee Related JP6599848B2 (ja) | 2013-05-10 | 2014-05-09 | ソルタギング可能なタンパク質を有する赤血球のｉｎｖｉｔｒｏ生成 |
| JP2019182854A Expired - Fee Related JP6960177B2 (ja) | 2013-05-10 | 2019-10-03 | ソルタギング可能なタンパク質を有する赤血球のｉｎ ｖｉｔｒｏ生成 |
| JP2021163272A Pending JP2022001063A (ja) | 2013-05-10 | 2021-10-04 | ソルタギング可能なタンパク質を有する赤血球のｉｎ ｖｉｔｒｏ生成 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019182854A Expired - Fee Related JP6960177B2 (ja) | 2013-05-10 | 2019-10-03 | ソルタギング可能なタンパク質を有する赤血球のｉｎ ｖｉｔｒｏ生成 |
| JP2021163272A Pending JP2022001063A (ja) | 2013-05-10 | 2021-10-04 | ソルタギング可能なタンパク質を有する赤血球のｉｎ ｖｉｔｒｏ生成 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10471099B2 (https=) |
| EP (4) | EP3546484B1 (https=) |
| JP (3) | JP6599848B2 (https=) |
| AU (2) | AU2014262474B2 (https=) |
| ES (1) | ES2901383T3 (https=) |
| HK (1) | HK1222662A1 (https=) |
| WO (1) | WO2014183071A2 (https=) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10081684B2 (en) | 2011-06-28 | 2018-09-25 | Whitehead Institute For Biomedical Research | Using sortases to install click chemistry handles for protein ligation |
| JP6261500B2 (ja) | 2011-07-22 | 2018-01-17 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ヌクレアーゼ切断特異性の評価および改善 |
| US10260038B2 (en) | 2013-05-10 | 2019-04-16 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
| EP3546484B1 (en) | 2013-05-10 | 2021-09-08 | Whitehead Institute for Biomedical Research | In vitro production of red blood cells with sortaggable proteins |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| AU2014346559B2 (en) | 2013-11-07 | 2020-07-09 | Editas Medicine,Inc. | CRISPR-related methods and compositions with governing gRNAs |
| US10556024B2 (en) | 2013-11-13 | 2020-02-11 | Whitehead Institute For Biomedical Research | 18F labeling of proteins using sortases |
| AU2014348683B2 (en) | 2013-11-18 | 2020-11-05 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| ES2865825T3 (es) | 2014-04-01 | 2021-10-18 | Rubius Therapeutics Inc | Procedimientos y composiciones para inmunomodulación |
| WO2016022363A2 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| US10053683B2 (en) | 2014-10-03 | 2018-08-21 | Whitehead Institute For Biomedical Research | Intercellular labeling of ligand-receptor interactions |
| SG11201704627XA (en) | 2014-12-17 | 2017-07-28 | Hoffmann La Roche | Enzymatic one-pot reaction for double polypeptide conjugation in a single step using sortase |
| CN107109463B (zh) | 2014-12-17 | 2020-12-29 | 豪夫迈·罗氏有限公司 | 键形成酶的活性测定 |
| US20180135012A1 (en) * | 2015-05-13 | 2018-05-17 | Rubius Therapeutics, Inc. | Membrane-receiver complex therapeutics |
| WO2017050874A1 (en) | 2015-09-25 | 2017-03-30 | F. Hoffmann-La Roche Ag | Process for producing thioesters employing a sortase a |
| WO2017050872A1 (en) | 2015-09-25 | 2017-03-30 | F. Hoffmann-La Roche Ag | Transamidation employing sortase a in deep eutectic solvents |
| ES2941968T3 (es) | 2015-10-01 | 2023-05-29 | The Whitehead Institute For Biomedical Res | Marcaje de anticuerpos |
| JP7109784B2 (ja) | 2015-10-23 | 2022-08-01 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 遺伝子編集のための進化したＣａｓ９蛋白質 |
| AU2017207736A1 (en) * | 2016-01-11 | 2018-07-12 | Rubius Therapeutics, Inc. | Compositions and methods related to multimodal therapeutic cell systems for immune indications |
| CN108778318B (zh) * | 2016-01-14 | 2022-05-03 | 北卡罗莱纳州立大学 | 葡萄糖响应性胰岛素递送组合物和方法 |
| KR102547316B1 (ko) | 2016-08-03 | 2023-06-23 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
| US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| EP3526320A1 (en) | 2016-10-14 | 2019-08-21 | President and Fellows of Harvard College | Aav delivery of nucleobase editors |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| KR20190091497A (ko) | 2016-12-02 | 2019-08-06 | 루비우스 테라퓨틱스, 아이엔씨. | 고형 종양으로의 침투를 위한 세포 시스템과 관련된 조성물 및 방법 |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| CN110520522A (zh) * | 2017-02-17 | 2019-11-29 | 鲁比厄斯治疗法股份有限公司 | 功能化红系细胞 |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| JP2020510038A (ja) | 2017-03-09 | 2020-04-02 | プレジデント アンド フェローズ オブ ハーバード カレッジ | がんワクチン |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| CA3057192A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| US20200172867A1 (en) | 2017-07-19 | 2020-06-04 | Rubius Therapeutics, Inc. | Compositions and methods related to multimodal therapeutic cell systems for cardiometabolic disease |
| EP3654991A1 (en) | 2017-07-19 | 2020-05-27 | Rubius Therapeutics, Inc. | Compositions and methods related to multimodal therapeutic cell systems for infectious disease |
| WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE) |
| AU2018316166A1 (en) * | 2017-08-07 | 2020-02-06 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
| US10960071B2 (en) * | 2017-08-07 | 2021-03-30 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
| EP4328314A3 (en) | 2017-08-22 | 2024-03-20 | Tessera Therapeutics, Inc. | Lipid nanoparticle methods and compositions for producing engineered erythroid cells |
| WO2019040649A1 (en) * | 2017-08-23 | 2019-02-28 | Whitehead Institute For Biomedical Research | PRODUCTION OF REDUCED GLOBULATES AND USES THEREOF |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| KR20250107288A (ko) | 2017-10-16 | 2025-07-11 | 더 브로드 인스티튜트, 인코퍼레이티드 | 아데노신 염기 편집제의 용도 |
| WO2019090148A2 (en) | 2017-11-03 | 2019-05-09 | Rubius Therapeutics, Inc. | Compositions and methods related to therapeutic cell systems for tumor growth inhibition |
| WO2019118949A1 (en) | 2017-12-15 | 2019-06-20 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| RU2021138205A (ru) * | 2017-12-23 | 2022-01-20 | Рубиус Терапьютикс, Инк. | Искусственные антигенпрезентирующие клетки и способы их применения |
| WO2019133881A1 (en) | 2017-12-29 | 2019-07-04 | Rubius Therapeutics, Inc. | Gene editing and targeted transcriptional modulation for enginerering erythroid cells |
| US20190330591A1 (en) | 2018-01-10 | 2019-10-31 | Rubius Therapeutics, Inc. | Amplifiable rnas for therapeutic cell systems |
| EP3762422A1 (en) | 2018-03-08 | 2021-01-13 | Rubius Therapeutics, Inc. | Therapeutic cell systems and methods for treating cancer and infectious diseases |
| EP3797160A1 (en) | 2018-05-23 | 2021-03-31 | The Broad Institute Inc. | Base editors and uses thereof |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| WO2020060496A1 (en) * | 2018-09-21 | 2020-03-26 | City University Of Hong Kong | Surface modified extracellular vesicles |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| JP2022513705A (ja) | 2018-12-03 | 2022-02-09 | ルビウス セラピューティクス， インコーポレイテッド | Ｈｌａ－ｅおよびｈｌａ－ｇ分子を含む人工抗原提示細胞、ならびに使用の方法 |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| SG11202109073VA (en) * | 2019-02-20 | 2021-09-29 | Rubius Therapeutics Inc | Engineered erythroid cells including loadable antigen-presenting polypeptides and methods of use |
| JP7657726B2 (ja) | 2019-03-19 | 2025-04-07 | ザ ブロード インスティテュート，インコーポレーテッド | 編集ヌクレオチド配列を編集するための方法および組成物 |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| JP2022530130A (ja) | 2019-04-26 | 2022-06-27 | ルビウス セラピューティクス， インコーポレイテッド | 除核赤血球細胞を含む緩衝組成物 |
| EP3976762A1 (en) | 2019-05-24 | 2022-04-06 | Rubius Therapeutics, Inc. | Methods of generating enucleated erythroid cells |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| CN115038784A (zh) | 2019-11-04 | 2022-09-09 | 鲁比厄斯治疗法股份有限公司 | 使用肌-肌醇产生去核红系细胞的方法 |
| EP4055148A1 (en) | 2019-11-04 | 2022-09-14 | Rubius Therapeutics, Inc. | Methods of generating enucleated erythroid cells using taurine or hypotaurine |
| US20230050813A1 (en) | 2020-01-13 | 2023-02-16 | Carmine Therapeutics Pte. Ltd. | Nucleic acid loaded red blood cell extracellular vesicles |
| CN115397395A (zh) * | 2020-02-07 | 2022-11-25 | 加利福尼亚大学董事会 | 生物工程去核细胞的方法和用途 |
| CN115151636A (zh) | 2020-02-10 | 2022-10-04 | 鲁比厄斯治疗法股份有限公司 | 包含hla-g多肽的经工程改造的红系细胞及其使用方法 |
| WO2021185360A1 (en) * | 2020-03-20 | 2021-09-23 | Westlake Therapeutics (Hangzhou) Co., Limited | Novel truncated sortase variants |
| DE112021002672T5 (de) | 2020-05-08 | 2023-04-13 | President And Fellows Of Harvard College | Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz |
| EP4149440A1 (en) | 2020-05-11 | 2023-03-22 | Erytech Pharma | Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof |
| US20230399616A1 (en) * | 2020-10-30 | 2023-12-14 | Westlake Therapeutics (Hangzhou) Co. Limited | Modified Red Blood Cells and Uses Thereof for Delivering Agents |
| CA3201499A1 (en) | 2020-11-13 | 2022-05-19 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
| TW202241471A (zh) | 2021-01-08 | 2022-11-01 | 美商盧比亞斯治療公司 | 提高個體中NKp30陽性淋巴球的方法及其用途 |
| TW202241470A (zh) | 2021-01-08 | 2022-11-01 | 美商盧比亞斯治療公司 | 治療人類個體腫瘤之方法 |
| EP4284916A4 (en) * | 2021-01-29 | 2025-08-06 | Nat Univ Singapore | SURFACE-MODIFIED RED BLOOD CELLS AND METHODS OF GENERATION THEREOF |
| CN116888258A (zh) * | 2021-02-04 | 2023-10-13 | 西湖生物医药科技(杭州)有限公司 | 修饰的红细胞及其治疗高尿酸血症和痛风的用途 |
| WO2022197548A1 (en) | 2021-03-14 | 2022-09-22 | Rubius Therapeutics, Inc. | Methods of increasing nkg2d-positive lymphocytes in a subject and uses thereof |
| WO2022211740A1 (en) | 2021-03-31 | 2022-10-06 | Carmine Therapeutics Pte. Ltd. | Extracellular vesicles loaded with at least two different nucleic acids |
| TW202317179A (zh) | 2021-06-03 | 2023-05-01 | 美商盧比亞斯治療公司 | 在個體中治療ｈｐｖ１６－陽性或ｈｐｖ１６－相關的癌症之方法 |
| CN117730143A (zh) * | 2021-07-13 | 2024-03-19 | 西湖生物医药科技(杭州)有限公司 | 通过缀合的n-末端甘氨酸修饰的细胞及其用途 |
| CN120152732A (zh) * | 2022-10-24 | 2025-06-13 | 西湖生物医药科技(上海)有限公司 | 诱导特异性免疫耐受的组合 |
| EP4694870A2 (en) * | 2023-04-12 | 2026-02-18 | Cytonus Therapeutics, Inc. | Manufacturing of therapeutic cells |
| WO2025006882A1 (en) * | 2023-06-30 | 2025-01-02 | The Children's Hospital Of Philadelphia | Click chemistry assisted cell surface engineering for restoring lentivirus entry |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5834256A (en) | 1993-06-11 | 1998-11-10 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
| US5670132A (en) | 1994-09-20 | 1997-09-23 | Immunomedics, Inc. | Modified radioantibody fragments for reduced renal uptake |
| US5728369A (en) | 1994-10-05 | 1998-03-17 | Immunomedics, Inc. | Radioactive phosphorus labeling of proteins for targeted radiotherapy |
| US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
| WO1997021824A2 (en) | 1995-12-15 | 1997-06-19 | Systemix, Inc. | Method for obtaining retroviral vector supernatant having high transduction efficiency |
| CA2365523A1 (en) | 1999-04-15 | 2000-10-26 | The Regents Of The University Of California | Identification of sortase gene |
| CA2413538A1 (en) | 2000-07-06 | 2002-01-17 | Bristol-Myers Squibb Pharma Company | Stable radiopharmaceutical compositions and methods for preparation thereof |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US6960473B2 (en) * | 2003-02-27 | 2005-11-01 | Istituto Superiore Di Sanita | In vitro mass production of human erythroid cells from the blood of normal donors and thalassemic patients |
| WO2005051976A2 (en) | 2003-11-20 | 2005-06-09 | Ansata Therapeutics, Inc. | Protein and peptide ligation processes and one-step purification processes |
| US20090098611A1 (en) | 2004-02-27 | 2009-04-16 | Wood David W | Self-cleaving affinity tags and methods of use |
| US8206979B2 (en) * | 2004-06-04 | 2012-06-26 | Universite Pierre et Marie Curie — Paris VI | Method for producing red blood cells |
| US8398956B2 (en) | 2007-01-11 | 2013-03-19 | Immunomedics, Inc. | In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| US8211656B2 (en) * | 2008-08-13 | 2012-07-03 | The Invention Science Fund I, Llc | Biological targeting compositions and methods of using the same |
| US20120034155A1 (en) | 2010-08-03 | 2012-02-09 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Artificial cells |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| US20100092470A1 (en) | 2008-09-22 | 2010-04-15 | Icb International, Inc. | Antibodies, analogs and uses thereof |
| JP2010115136A (ja) * | 2008-11-12 | 2010-05-27 | Teruyuki Nagamune | Ｎ末端標識膜蛋白質の作製方法、及びｎ末端標識膜蛋白質を表層に有する細胞 |
| WO2010078376A2 (en) | 2008-12-30 | 2010-07-08 | Ventana Medical Systems, Inc. | Fc-specific polymer-conjugated antibodies and their diagnostic use |
| WO2010087994A2 (en) | 2009-01-30 | 2010-08-05 | Whitehead Institute For Biomedical Research | Methods for ligation and uses thereof |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| TW201129384A (en) | 2010-02-10 | 2011-09-01 | Immunogen Inc | CD20 antibodies and uses thereof |
| ES2608937T3 (es) * | 2010-02-22 | 2017-04-17 | Université Pierre Et Marie Curie (Paris 6) | Medio de cultivo celular para el crecimiento y diferenciación de células del linaje hematopoyético |
| CN102892786B (zh) | 2010-03-11 | 2016-03-16 | Ucb医药有限公司 | Pd-1抗体 |
| EP2593469A4 (en) | 2010-04-20 | 2015-07-15 | Whitehead Biomedical Inst | MODIFIED POLYPEPTIDES AND PROTEINS AND ITS APPLICATION |
| WO2012142659A1 (en) | 2011-04-19 | 2012-10-26 | Baker Idi Heart And Diabetes Institute Holdings Limited | Site-selective modification of proteins |
| US10081684B2 (en) * | 2011-06-28 | 2018-09-25 | Whitehead Institute For Biomedical Research | Using sortases to install click chemistry handles for protein ligation |
| CN102559600A (zh) | 2011-12-29 | 2012-07-11 | 上海交通大学医学院 | 一种人工抗原递呈细胞及其在nk细胞扩增中的应用 |
| WO2013132317A1 (en) | 2012-03-07 | 2013-09-12 | Aurigene Discovery Technologies Limited | Peptidomimetic compounds as immunomodulators |
| AU2013245645A1 (en) | 2012-04-13 | 2014-11-13 | Whitehead Institute For Biomedical Research | Sortase- modified VHH domains and uses thereof |
| US20140030697A1 (en) | 2012-06-14 | 2014-01-30 | Massachusetts Institute Of Technology | Sortase-mediated modification of viral surface proteins |
| US9267127B2 (en) | 2012-06-21 | 2016-02-23 | President And Fellows Of Harvard College | Evolution of bond-forming enzymes |
| US9511350B2 (en) | 2013-05-10 | 2016-12-06 | Clean Diesel Technologies, Inc. (Cdti) | ZPGM Diesel Oxidation Catalysts and methods of making and using same |
| EP3546484B1 (en) | 2013-05-10 | 2021-09-08 | Whitehead Institute for Biomedical Research | In vitro production of red blood cells with sortaggable proteins |
| US10260038B2 (en) | 2013-05-10 | 2019-04-16 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
| WO2014186508A1 (en) | 2013-05-15 | 2014-11-20 | University Of Rechester | Human extensively self-renewing erythroblasts (esre) |
| WO2015051188A1 (en) | 2013-10-02 | 2015-04-09 | Washington University | Heterocyclic molecules for biomedical imaging and therapeutic applications |
| WO2015057863A1 (en) | 2013-10-15 | 2015-04-23 | Regents Of The University Of Minnesota | Triorthogonal reagents for dual protein conjugation |
| US10556024B2 (en) | 2013-11-13 | 2020-02-11 | Whitehead Institute For Biomedical Research | 18F labeling of proteins using sortases |
| US10053683B2 (en) | 2014-10-03 | 2018-08-21 | Whitehead Institute For Biomedical Research | Intercellular labeling of ligand-receptor interactions |
| US20180135012A1 (en) | 2015-05-13 | 2018-05-17 | Rubius Therapeutics, Inc. | Membrane-receiver complex therapeutics |
| ES2941968T3 (es) | 2015-10-01 | 2023-05-29 | The Whitehead Institute For Biomedical Res | Marcaje de anticuerpos |
| WO2019040649A1 (en) | 2017-08-23 | 2019-02-28 | Whitehead Institute For Biomedical Research | PRODUCTION OF REDUCED GLOBULATES AND USES THEREOF |
| EP3976762A1 (en) * | 2019-05-24 | 2022-04-06 | Rubius Therapeutics, Inc. | Methods of generating enucleated erythroid cells |
-
2014
- 2014-05-09 EP EP19171188.6A patent/EP3546484B1/en not_active Not-in-force
- 2014-05-09 HK HK16110752.9A patent/HK1222662A1/zh unknown
- 2014-05-09 EP EP19171190.2A patent/EP3546485A1/en not_active Withdrawn
- 2014-05-09 WO PCT/US2014/037554 patent/WO2014183071A2/en not_active Ceased
- 2014-05-09 EP EP19219550.1A patent/EP3693398A1/en not_active Withdrawn
- 2014-05-09 JP JP2016513129A patent/JP6599848B2/ja not_active Expired - Fee Related
- 2014-05-09 US US14/890,241 patent/US10471099B2/en active Active - Reinstated
- 2014-05-09 AU AU2014262474A patent/AU2014262474B2/en not_active Ceased
- 2014-05-09 ES ES19171188T patent/ES2901383T3/es active Active
- 2014-05-09 EP EP14795167.7A patent/EP2994491A4/en not_active Withdrawn
-
2018
- 2018-03-23 US US15/934,177 patent/US11266695B2/en active Active
-
2019
- 2019-09-16 US US16/572,425 patent/US11992505B2/en active Active
- 2019-10-03 JP JP2019182854A patent/JP6960177B2/ja not_active Expired - Fee Related
- 2019-12-16 AU AU2019283766A patent/AU2019283766B2/en not_active Ceased
-
2021
- 2021-10-04 JP JP2021163272A patent/JP2022001063A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016519933A5 (https=) | ||
| Yang et al. | High-mobility group box-1 and its role in angiogenesis | |
| PH12018502451A1 (en) | Brain delivery protein | |
| EP4289484A3 (en) | Anti-ctla-4 antibodies and methods of use thereof | |
| WO2014018858A3 (en) | Multimeric fusion protein vaccine and immunotherapeutic | |
| SA517380842B1 (ar) | بروتينات دمج لمستقبل إنترليوكين-2/إنترليوكين-2 ألفا وطرق الاستخدام | |
| MY157564A (en) | Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract | |
| WO2013088148A3 (en) | Method of treatment employing therapeutic t cell product from mobilised donors | |
| CN106659777A8 (zh) | 免疫原性组合产品 | |
| JP2012126742A5 (https=) | ||
| MX2020006822A (es) | Proteinas de fusion de anticuerpo de un solo dominio-citosina desaminasa. | |
| EA201591213A1 (ru) | Вакцины против вируса гепатита b | |
| AR056245A1 (es) | Membranas virales reconstituidas funcionales que contienen un coadyuvante | |
| WO2013076580A3 (en) | Recombinant proteins and their therapeutic uses | |
| MX2019001136A (es) | Partículas similares a virus con recubrimiento de alta densidad para inducir la expresión de anticuerpos. | |
| EA201891639A1 (ru) | Аминокислотные и пептидные конъюгаты и способ конъюгации | |
| WO2015095167A3 (en) | Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon | |
| MX387764B (es) | Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos. | |
| WO2015140172A3 (en) | A medicament for use in a method of inducing or extending a cellular cytotoxic immune response | |
| JP2016508143A5 (https=) | ||
| JP2018023397A5 (https=) | ||
| WO2014144621A3 (en) | Modified fc fusion proteins | |
| RU2019113989A (ru) | Лекарственное средство | |
| AR101597A1 (es) | Proteínas de fusión uti (inhibidor de tripsina urinaria) | |
| WO2018175740A8 (en) | Anti-tmeff1 antibodies and antibody drug conjugates |